• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Allakos Inc.

    4/9/25 4:30:54 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Allakos Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    01671P100

    (CUSIP Number)


    04/02/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    01671P100


    1Names of Reporting Persons

    Beryl Capital Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on 90,203,245 shares of Common Stock outstanding on March 5, 2025, as disclosed in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    01671P100


    1Names of Reporting Persons

    Beryl Capital Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.9 %
    12Type of Reporting Person (See Instructions)

    IA, PN

    Comment for Type of Reporting Person:  Percentage calculated based on 90,203,245 shares of Common Stock outstanding on March 5, 2025, as disclosed in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    01671P100


    1Names of Reporting Persons

    Beryl Capital Partners II LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,446,645.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,446,645.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,446,645.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.2 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on 90,203,245 shares of Common Stock outstanding on March 5, 2025, as disclosed in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    01671P100


    1Names of Reporting Persons

    David A. Witkin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,000,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,000,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on 90,203,245 shares of Common Stock outstanding on March 5, 2025, as disclosed in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Allakos Inc.
    (b)Address of issuer's principal executive offices:

    825 Industrial Road, Suite 500, San Carlos, CA 94070
    Item 2. 
    (a)Name of person filing:

    Beryl Capital Management LLC, a Delaware limited liability company ("Beryl") Beryl Capital Management LP, a Delaware limited partnership ("Beryl GP") Beryl Capital Partners II LP, a Delaware limited partnership (the "Partnership") David A. Witkin Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    225 Avenue I, Suite 205 Redondo Beach, CA 90277
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    01671P100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Beryl: 8,000,000 Beryl GP: 8,000,000 Partnership: 6,446,645 David A Witkin: 8,000,000
    (b)Percent of class:

    Beryl: 8.9% Beryl GP: 8.9% Partnership: 7.2% David A. Witkin: 8.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0

     (ii) Shared power to vote or to direct the vote:

    Beryl: 8,000,000 Beryl GP: 8,000,000 Partnership: 6,446,645 David A Witkin: 8,000,000

     (iii) Sole power to dispose or to direct the disposition of:

    Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Beryl: 8,000,000 Beryl GP: 8,000,000 Partnership: 6,446,645 David A Witkin: 8,000,000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Beryl is the investment adviser to the Partnership and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of the Partnership and other private investment funds. Mr. Witkin is the control person of Beryl.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Beryl Capital Management LLC
     
    Signature:/s/ Andrew Nelson
    Name/Title:Chief Operating Officer
    Date:04/09/2025
     
    Beryl Capital Management LP
     
    Signature:/s/ Andrew Nelson
    Name/Title:Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
    Date:04/09/2025
     
    Beryl Capital Partners II LP
     
    Signature:/s/ Andrew Nelson
    Name/Title:COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
    Date:04/09/2025
     
    David A. Witkin
     
    Signature:/s/ David A. Witkin
    Name/Title:Reporting person
    Date:04/09/2025
    Exhibit Information

    Exhibit 99.1 - Agreement Regrding Joint Filing of Statement on Schedule 13D or 13G

    Get the next $ALLK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLK

    DatePrice TargetRatingAnalyst
    1/17/2024$6.00 → $1.50Buy → Hold
    Jefferies
    1/16/2024Overweight → Neutral
    Cantor Fitzgerald
    12/18/2023Mkt Perform → Outperform
    William Blair
    12/8/2023$9.00 → $6.00Buy
    Jefferies
    9/27/2023$11.00Mkt Outperform
    JMP Securities
    5/12/2023$6.00 → $9.00Hold → Buy
    Jefferies
    3/7/2023$22.00Overweight
    Piper Sandler
    9/12/2022$2.00Neutral → Underperform
    SMBC Nikko
    More analyst ratings

    $ALLK
    SEC Filings

    View All

    SEC Form 15-12G filed by Allakos Inc.

    15-12G - Allakos Inc. (0001564824) (Filer)

    5/27/25 9:00:14 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Allakos Inc.

    SCHEDULE 13G/A - Allakos Inc. (0001564824) (Subject)

    5/19/25 6:42:25 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Allakos Inc.

    SCHEDULE 13D/A - Allakos Inc. (0001564824) (Subject)

    5/19/25 4:15:11 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

    SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ( "Concentra") will acquire Allakos for $0.33 in cash per share of Allakos common stock ("Allakos Common Stock"). Allakos' Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos' Transaction Committee, has appro

    4/2/25 8:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

    SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos Events Reported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025.Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives. Cash Guidance Allakos ended the fourth qua

    3/12/25 4:02:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

    SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

    2/11/25 11:30:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bvf Partners L P/Il returned 16,312,872 shares to the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/19/25 6:45:29 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Walker Paul Edward returned 6,147,260 shares to the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/15/25 4:28:27 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Tomasi Adam returned 533,420 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/15/25 4:08:04 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allakos downgraded by Jefferies with a new price target

    Jefferies downgraded Allakos from Buy to Hold and set a new price target of $1.50 from $6.00 previously

    1/17/24 7:08:59 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Allakos from Overweight to Neutral

    1/16/24 1:35:19 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos upgraded by William Blair

    William Blair upgraded Allakos from Mkt Perform to Outperform

    12/18/23 6:44:17 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Financials

    Live finance-specific insights

    View All

    Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

    – AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (NASDAQ:ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical developme

    1/27/25 7:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Announces a Restructuring to Focus on Development of AK006

    Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa randomized, double-blind, placebo-controlled trial in patients with CSUa subcutaneous AK006 Phase 1 PK and bioavailability trial Management to host conference call and webcast today at 8:00 am E.T. SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 c

    1/16/24 7:02:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

    – Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK). "We are disappointed that these trials did not m

    1/16/24 7:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Leadership Updates

    Live Leadership Updates

    View All

    Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

    SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

    2/11/25 11:30:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Appoints Neil Graham to its Board of Directors

    SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph

    8/30/23 4:05:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

    SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well

    8/2/23 4:05:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Allakos Inc.

    SC 13G - Allakos Inc. (0001564824) (Subject)

    11/12/24 9:50:12 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allakos Inc.

    SC 13G/A - Allakos Inc. (0001564824) (Subject)

    7/8/24 4:32:41 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Allakos Inc. (Amendment)

    SC 13G/A - Allakos Inc. (0001564824) (Subject)

    2/14/24 4:58:16 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care